18F-fluorothymidine - MerckAlternative Names: 18F-FLT (3'-deoxy-3'[18F]-fluorothymidine) - Merck; 18F-FLT - Merck; 18F-FLT-PET - Merck
Latest Information Update: 27 Jul 2015
At a glance
- Originator Merck & Co
- Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 27 Dec 2011 Merck completes a phase II trial in Breast cancer (diagnosis) in USA and South Korea (NCT01015131)
- 02 Jul 2011 Merck completes enrolment in its phase II trial for Breast cancer (diagnosis) in USA and South Korea (NCT01015131)